Prostate-Specific Membrane Antigen Expression in Metastatic Angiosarcoma Detected on 18F-PMSA PET/CT: A New Potential Prognostic Marker.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Feb 2022
01 Feb 2022
Historique:
pubmed:
27
6
2021
medline:
13
1
2022
entrez:
26
6
2021
Statut:
ppublish
Résumé
18F-PSMA is a promising tracer for both staging and detection of biochemical recurrence in prostate cancer. PSMA is also expressed in the endothelium of tumor-associated neovasculature of various solid malignancies possibly due to tumor-associated angiogenic factors and endothelial cell sprouting. We report a case of a 59-year-old man with known case of prostate cancer underwent 18F-PSMA for restaging. 18F-PSMA PET/CT shows multiple lytic bone lesions with high PSMA expression. Histopathological evaluation showed metastatic angiosarcoma. 18F-PSMA expression in the angiosarcoma can be potentially guided to radionuclide legend therapy.
Identifiants
pubmed: 34172597
doi: 10.1097/RLU.0000000000003780
pii: 00003072-202202000-00046
doi:
Substances chimiques
Gallium Radioisotopes
0
Pyrrolidines
0
pyrrolidin-3-yl-methanesulfonic acid
95596-30-8
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e147-e148Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Young RJ, Brown NJ, Reed MW, et al. Angiosarcoma. Lancet Oncol . 2010;11:983–991.
Mark RJ, Poen JC, Tran LM, et al. Angiosarcoma. A report of 67 patients and a review of the literature. Cancer . 1996;77:2400–2406.
Giesel FL, Hadaschik B, Cardinale J, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging . 2017;44:678–688.
Giesel FL, Will L, Kesch C, et al. Biochemical recurrence of prostate cancer: initial results with [(18)F]PSMA-1007 PET/CT. J Nucl Med . 2018;59:632–635.
Marafi F, Sasikumar A, Fathallah W, et al. 18 F-PSMA 1007 brain PET/CT imaging in glioma recurrence. Clin Nucl Med . 2020;45:e61–e62.
Marafi F, Sasikumar A, Al-Terki A, et al. 18 F-PSMA 1007 in suspected renal cell carcinoma. Clin Nucl Med . 2020;45:377–378.
Marafi F, Sasikumar A, Alfeeli M, et al. 18 F-PSMA 1007 uptake in a man with metastatic breast cancer. Clin Nucl Med . 2020;45:e276–e278.
Chang SS, Reuter VE, Heston WD, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res . 1999;59:3192–3198.
Conway RE, Petrovic N, Li Z, et al. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol . 2006;26:5310–5324.
Haffner MC, Laimer J, Chaux A, et al. High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Mod Pathol . 2012;25:1079–1085.